Serum vascular endothelial growth factor, transforming growth factor β1, and nitric oxide levels in patients with psoriasis vulgaris: their correlation to disease severity
- PMID: 24659464
- PMCID: PMC6807330
- DOI: 10.1002/jcla.21717
Serum vascular endothelial growth factor, transforming growth factor β1, and nitric oxide levels in patients with psoriasis vulgaris: their correlation to disease severity
Abstract
Background: Vascular endothelial growth factor (VEGF), transforming growth factor β1 (TGF-β1), and nitric oxide (NO) have been reported to be contributory factors to the pathogenesis of psoriasis vulgaris. In the current study, we aimed to investigate the association between the levels of VEGF, TGF-β1, and NO and psoriasis severity (as expressed by psoriasis area severity index, PASI).
Methods: Fifty-eight patients with psoriasis vulgaris and twenty-two controls were included in the study. The serum levels of VEGF and TGF-β1 were estimated by ELISA technique. The serum levels of NO were determined by colorimetric method.
Results: The serum levels of VEGF, TGF-β1, and NO were significantly higher in patients than controls. Moreover, the serum levels of the studied biochemical variables in patients with severe disease activity were significantly higher than mild cases. The duration of disease showed significant positive correlations with each VEGF (r = 0.35, P < 0.01) and TGF-β1 (r = 0.41, P < 0.05). In addition, the PASI score was significantly positively correlated with VEGF (r = 0.65, P < 0.001), TGF-β1 (r = 0.31, P < 0.05), and NO (r = 0.51, P < 0.001).
Conclusion: These findings suggest an association between psoriasis disease severity and serum levels of VEGF, TGF-β1, and NO, which can be recognized as markers of the psoriasis severity. The modulation of their production may represent a therapeutic potential strategy for psoriasis.
Keywords: NO; TGF-β1; VEGF; patients; psoriasis vulgaris.
© 2014 Wiley Periodicals, Inc.
Conflict of interest statement
None declared.
Figures



Similar articles
-
Serum and tissue expression of transforming growth factor beta 1 in psoriasis.J Eur Acad Dermatol Venereol. 2009 Apr;23(4):406-9. doi: 10.1111/j.1468-3083.2008.03064.x. J Eur Acad Dermatol Venereol. 2009. PMID: 19175705
-
Serum levels of transforming growth factor-beta1 in patients with mild psoriasis vulgaris and effect of treatment with biological drugs.Clin Exp Dermatol. 2009 Jul;34(5):582-6. doi: 10.1111/j.1365-2230.2008.03026.x. Epub 2008 Dec 15. Clin Exp Dermatol. 2009. PMID: 19094132
-
The relationship between transforming growth factor-beta1, vascular endothelial growth factor, nitric oxide and Hashimoto's thyroiditis.Int Immunopharmacol. 2009 Feb;9(2):212-5. doi: 10.1016/j.intimp.2008.11.003. Epub 2008 Nov 24. Int Immunopharmacol. 2009. PMID: 19028605
-
Serum concentrations of transforming growth factor beta 1 in patients with psoriasis vulgaris.Acta Dermatovenerol Croat. 2004;12(1):2-6. Acta Dermatovenerol Croat. 2004. PMID: 15072741
-
Effects of Narrow Band Ultraviolet B on Serum Levels of Vascular Endothelial Growth Factor and Interleukin-8 in Patients with Psoriasis.Am J Ther. 2016 May-Jun;23(3):e655-62. doi: 10.1097/MJT.0000000000000330. Am J Ther. 2016. PMID: 26308328 Review.
Cited by
-
Ustekinumab therapy changes the transcriptional activity pattern of TGF-β1-3 genes.Postepy Dermatol Alergol. 2021 Apr;38(2):244-248. doi: 10.5114/ada.2019.91504. Epub 2020 Jan 9. Postepy Dermatol Alergol. 2021. PMID: 34408592 Free PMC article.
-
MiR-150 regulates human keratinocyte proliferation in hypoxic conditions through targeting HIF-1α and VEGFA: Implications for psoriasis treatment.PLoS One. 2017 Apr 11;12(4):e0175459. doi: 10.1371/journal.pone.0175459. eCollection 2017. PLoS One. 2017. PMID: 28399173 Free PMC article.
-
Bone phenotypes in rheumatology - there is more to bone than just bone.BMC Musculoskelet Disord. 2020 Nov 28;21(1):789. doi: 10.1186/s12891-020-03804-2. BMC Musculoskelet Disord. 2020. PMID: 33248451 Free PMC article. Review.
-
Circulating Cell-Free DNA as Inflammatory Marker in Egyptian Psoriasis Patients.Psoriasis (Auckl). 2020 May 21;10:13-21. doi: 10.2147/PTT.S241750. eCollection 2020. Psoriasis (Auckl). 2020. PMID: 32607312 Free PMC article.
-
Evaluation of selected mechanisms of immune tolerance in psoriasis.Postepy Dermatol Alergol. 2019 Jun;36(3):319-328. doi: 10.5114/ada.2019.85641. Epub 2019 Jun 19. Postepy Dermatol Alergol. 2019. PMID: 31333349 Free PMC article.
References
-
- Simonetti O, Lucarini G, Goteri G, et al. VEGF is likely a key factor in the link between inflammation and angiogenesis in psoriasis: Results of an immunohistochemical study. Int J Immunopathol Pharmacol 2006;19:751–760. - PubMed
-
- Henno A, Blacher S, Lambert CA, et al. Histological and transcriptional study of angiogenesis and lymphangiogenesis in uninvolved skin, acute pinpoint lesions and established psoriasis plaques: An approach of vascular development chronology in psoriasis. J Dermatol Sci 2010;57:162–169. - PubMed
-
- Micali G, Lacarrubba F, Musumeci ML, Massimino D, Nasca MR. Cutaneous vascular patterns in psoriasis. Int J Dermatol 2010;49(3):249–256. - PubMed
-
- Keck PJ, Hauser SD, Krivi G, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989;246:1309–1312. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical